Furthermore, we found that when treated with a single drug (individuals with PD-L1 TPS ≥ 50%) and combined chemotherapy (regardless of tumor cell PD-L1 expression) for advanced or metastatic NSCLC, pembrolizumab increased the OS compared to platinum-based chemotherapy. Here, CD274 is linked to non-small cell lung carcinoma.